NCT06620510Completed
Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea
A Multicenter, Retrospective Data Analysis Study on the Long-term Survival Rate of the 'Immuncell-LC Goups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea
Source: ClinicalTrials.gov · Last updated 15 Aug 2025
Brief summary (registry, in English)
To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 230 (actual)
- First submitted
- 26 Sept 2024
- Start date
- 30 Sept 2024
- Primary completion date
- 5 Dec 2024
- Lead sponsor
- GC Cell Corporation
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06620510
What you commit to
- Study type: Observational
- Participants enrolled: 230
- From 30 Sept 2024 to the primary completion date, 5 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- NA
Who the study is looking for
- Patients of participated in the(ClinicalTrials.gov Identifier:NCT00699816)clinical trial.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.